Design Therapeutics, Inc.’s DSGN share price has dipped by 5.42%, which has investors questioning if this is right time to ...

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the ...

We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

Aaron was born with muscular dystrophy and suffered a stroke in 2023, then spent much of the following year recovering in the Midwest because of Maui's limited medical resources. "It was beyond ...

About Myotonic Dystrophy Type 1 Myotonic dystrophy type 1 (DM1) is an underrecognized, autosomal dominantly inherited, progressive and often fatal disease caused by a triplet-repeat in the DMPK ...

for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease ...

Surface Transportation Board Chairman-designate Patrick Fuchs speaks at the American Short Line and Regional Railroad Association conference, April 8, 2025. (Photo: Stuart Chirls/FreightWaves) DENVER ...

Patients at risk for FECD should undergo genetic screening to help assess their risk of vision loss. Genetic screening for CTG18.1 expansions can identify patients at elevated risk of vision loss ...

Global Duchenne Muscular Dystrophy Drugs Market value attained USD 3.9 Billion in 2025. The market will achieve USD 6.5 Billion during 2034 with a growth rate (CAGR) of 10.96% during the forecast ...